S'abonner

Differential medication attitudes to antihypertensive and mood stabilizing agents in response to an automated text-messaging adherence enhancement intervention - 20/05/20

Doi : 10.1016/j.jbct.2020.03.015 
Peter J. Klein a, Michelle E. Aebi a, b, Martha Sajatovic a, b, Colin Depp c, David J. Moore c, Carol Blixen a, b, Jennifer B. Levin a, b,
a Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA 
b Neurological, Behavioral Outcomes Center, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USA 
c Department of Psychiatry, University of California San Diego, San Diego, CA, 92092, USA 

Corresponding author. Case Western Reserve University School of Medicine, 10524 Euclid Ave., Cleveland, Ohio, 44106, USA.Case Western Reserve University School of Medicine10524 Euclid Ave.Cleveland, Ohio44106USA

Abstract

Individuals with serious mental illnesses such as bipolar disorder (BD) are at an increased risk for poor medication adherence compared to the general population. Individuals with BD also have high rates of chronic comorbid medical conditions like hypertension (HTN), diabetes, and cardiovascular disease. Cognitive-behavioral therapies often integrate strategies to improve medication adherence by targeting medication attitudes and self-efficacy, but the pathway toward behavior change needs further investigation. This 3-month prospective, single-arm cohort study tested an automated SMS intervention entitled Individualized Texting for Adherence Building-Cardiovascular (iTAB-CV) in 38 participants with BD and HTN. The Tablets Routine Questionnaire (TRQ) measures the percentage of BD and HTN non-adherence over the past week and the past month. Attitudinal and habit measures including the Brief Illness Perception Questionnaire (Brief IPQ), the Medication Adherence Self-Efficacy Scale-Revised (MASES-R), the Self-Report Habit Index (SRHI), the Beliefs about Medicines Questionnaire (BMQ), and the Attitudes toward Mood Stabilizers Questionnaire (AMSQ) were given for BD and HTN medications. Correlational analyses were run to determine the associations between BD and HTN attitudinal and habit indices. Additionally, longitudinal analyses were conducted to determine if attitudes changed over time as a function of a 2-month mobile-health intervention. Illness attitudes towards BD were worse than towards HTN at the start of the study. Attitudes toward BD and towards mood-stabilizing drugs as well as antihypertensives improved following a mHealth intervention aimed at improving adherence. Furthermore, self-efficacy and habit strength for both BD and HTN drugs were correlated and were responsive to the intervention, with most of the change occurring after the first month of the intervention and not requiring the addition of the explicit reminders. Participants who received iTAB-CV showed improved attitudes towards BD and mood-stabilizing medication, and had an improvement in self-efficacy and habit strength towards taking both BD and HTN medications. Increased attention to mechanisms of change in mHealth interventions for adherence may facilitate impact. It should be noted that the methodology of the study limits drawing causal conclusions and suggests the need for a randomized control trial.

Le texte complet de cet article est disponible en PDF.

Keywords : Hypertension, Mobile health, m-Health, Bipolar, Adherence, Attitudes


Plan


© 2020  Association Française de Therapie Comportementale et Cognitive. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 30 - N° 1

P. 57-64 - avril 2020 Retour au numéro
Article précédent Article précédent
  • Understanding the evolving preferences for use of health information technology among adults with self reported anxiety and depression in the U.S
  • Henry Kosorochi Onyeaka, Hannah Wisniewski, Philip Henson, John Torous
| Article suivant Article suivant
  • A brief online intervention to address aggression in the context of emotion-related impulsivity for those treated for bipolar disorder: Feasibility, acceptability and pilot outcome data
  • Sheri L. Johnson, Devon B. Sandel, Mackenzie Zisser, Jennifer G. Pearlstein, Benjamin A. Swerdlow, Amy H. Sanchez, Ephrem Fernandez, Charles S. Carver

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.